Q3 FY25 saw 21% YoY revenue growth and a 95% YoY jump in EBITDA, with margins reaching 24.3%. All segments contributed to growth, major CapEx projects are on track, and order visibility remains strong for FY26, especially in specialty chemicals and CDMO.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.